Who are NS (0.9%)'s main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fluid resuscitation with Ringer Lactate, Normal Saline (0.9% NaCl), Saline isotonic, Normal saline (100ml), Isotonic solution (NaCl 0.9%), Isotone saline water.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/ns-0-9.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

NS (0.9%) — Competitive Intelligence Brief

NS (0.9%) (NS (0.9%)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Crystalloid fluid / Electrolyte solution. Area: Supportive Care / Fluid Management.

phase 3 Crystalloid fluid / Electrolyte solution Supportive Care / Fluid Management Small molecule Live · refreshed every 30 min

Target snapshot

NS (0.9%) (NS (0.9%)) — Ministry of Health, Spain. Normal saline (0.9% sodium chloride solution) provides isotonic fluid replacement and maintains electrolyte balance.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class
NS (0.9%) TARGET	NS (0.9%)	Ministry of Health, Spain	phase 3	Crystalloid fluid / Electrolyte solution
Fluid resuscitation with Ringer Lactate	Fluid resuscitation with Ringer Lactate	Centre Hospitalier Universitaire de Nice	marketed	Crystalloid fluid / Electrolyte solution
Normal Saline (0.9% NaCl)	Normal Saline (0.9% NaCl)	Hennepin Healthcare Research Institute	marketed	Crystalloid fluid / Electrolyte solution
Saline isotonic	Saline isotonic	Daniel Hägi-Pedersen	marketed	Crystalloid fluid / Electrolyte solution
Normal saline (100ml)	Normal saline (100ml)	Meshalkin Research Institute of Pathology of Circulation	marketed	Crystalloid fluid / Electrolyte solution
Isotonic solution (NaCl 0.9%)	Isotonic solution (NaCl 0.9%)	IRCCS Burlo Garofolo	phase 3	Crystalloid fluid / Electrolyte solution
Isotone saline water	Isotone saline water	Helse Nord-Trøndelag HF	phase 3	Crystalloid fluid / Electrolyte solution

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Crystalloid fluid / Electrolyte solution class)

Centre Hospitalier Universitaire de Nice · 1 drug in this class
Daniel Hägi-Pedersen · 1 drug in this class
Helse Nord-Trøndelag HF · 1 drug in this class
Hennepin Healthcare Research Institute · 1 drug in this class
IRCCS Burlo Garofolo · 1 drug in this class
Meshalkin Research Institute of Pathology of Circulation · 1 drug in this class
Ministry of Health, Spain · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). NS (0.9%) — Competitive Intelligence Brief. https://druglandscape.com/ci/ns-0-9. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab